UY34610A - Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos. - Google Patents
Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.Info
- Publication number
- UY34610A UY34610A UY0001034610A UY34610A UY34610A UY 34610 A UY34610 A UY 34610A UY 0001034610 A UY0001034610 A UY 0001034610A UY 34610 A UY34610 A UY 34610A UY 34610 A UY34610 A UY 34610A
- Authority
- UY
- Uruguay
- Prior art keywords
- pyroldicarboxamides
- condensed
- pharmaceutical agents
- pág
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Pirroldicarboxamidas condensadas y su uso como productos farmacéuticos. La presente invención se refiere a pirroldicarboxamidas condensadas de la fórmula I,en la que R1 a R9, X, m y n son como se definen en las reivindicaciones. Los compuestos de l a fórmula I son inhibidores del canal de potasio sensible a ácidos TASK-1 y adecuados para el tratamiento de enfermedades mediadas por el canal TASK-1 tales como arritmias, en particular arritmias auriculares como fibrilación auricular o aleteo auricular, y trastornos respiratorios,en particular trastornos respiratorios relacionados con el sueño como, por ejemplo, apnea del sueño.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305129 | 2012-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34610A true UY34610A (es) | 2013-09-30 |
Family
ID=47631438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001034610A UY34610A (es) | 2012-02-03 | 2013-02-01 | Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9284333B2 (es) |
| EP (1) | EP2809669B1 (es) |
| JP (1) | JP6126135B2 (es) |
| KR (1) | KR102017362B1 (es) |
| CN (1) | CN104169281B (es) |
| AR (1) | AR089863A1 (es) |
| AU (1) | AU2013214226B2 (es) |
| BR (1) | BR112014018767B1 (es) |
| CA (1) | CA2860933C (es) |
| CY (1) | CY1119108T1 (es) |
| DK (1) | DK2809669T3 (es) |
| ES (1) | ES2623167T3 (es) |
| HR (1) | HRP20170618T1 (es) |
| HU (1) | HUE031729T2 (es) |
| LT (1) | LT2809669T (es) |
| MX (1) | MX350793B (es) |
| PL (1) | PL2809669T3 (es) |
| PT (1) | PT2809669T (es) |
| RU (1) | RU2650111C2 (es) |
| SG (1) | SG11201403852UA (es) |
| SI (1) | SI2809669T1 (es) |
| UY (1) | UY34610A (es) |
| WO (1) | WO2013113860A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017097671A1 (de) * | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
| AU2016365676A1 (en) | 2015-12-10 | 2018-06-07 | Bayer Pharma Aktiengesellschaft | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of TASK-1 and TASK-2 channels, for the treatment of sleep-related breathing disorders |
| CA3009609C (en) | 2015-12-25 | 2023-09-26 | Takeda Pharmaceutical Company Limited | Prevention and treatment of heart failure |
| JP7002444B2 (ja) | 2016-03-28 | 2022-01-20 | 武田薬品工業株式会社 | 医薬 |
| JOP20190005A1 (ar) * | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| EP3537961A1 (en) | 2016-11-10 | 2019-09-18 | The Research Foundation for The State University of New York | System, method and biomarkers for airway obstruction |
| RU2768473C2 (ru) | 2017-04-27 | 2022-03-24 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение |
| JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2020035541A1 (en) | 2018-08-15 | 2020-02-20 | Universität Heidelberg | Task-1 inhibitors for treatment of atrial arrhythmias |
| US20240166645A1 (en) * | 2021-02-08 | 2024-05-23 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Pyridopyrimidinone derivative, preparation method therefor, and use thereof |
| WO2023225177A1 (en) * | 2022-05-19 | 2023-11-23 | Enalare Therapeutics Inc. | Methods and pharmaceutical compositions to treat respiratory depression in patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU83327A1 (fr) | 1981-04-29 | 1983-03-24 | Midit | Procede de preparation de derives de 1,4-thiazine,leur utilisation ainsi que compositions contenant ces derives |
| EP0447704A1 (en) | 1990-03-21 | 1991-09-25 | Smithkline Beecham Farmaceutici S.p.A. | N-Acylated azacyclic compounds, processes for their preparations and their use as medications |
| US7030112B2 (en) | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| DE10332685A1 (de) | 2003-07-18 | 2005-02-17 | Bayer Healthcare Ag | Vorhof-selektiv exprimierte Kaliumkanäle |
| DE102005028845A1 (de) * | 2005-06-22 | 2006-12-28 | Sanofi-Aventis Deutschland Gmbh | Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
| DE102005028862A1 (de) * | 2005-06-22 | 2007-01-11 | Sanofi-Aventis Deutschland Gmbh | Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| JP5161871B2 (ja) * | 2006-04-27 | 2013-03-13 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｔａｓｋ−１およびｔａｓｋ−３イオンチャンネルの阻害剤 |
| WO2008053319A1 (en) | 2006-10-30 | 2008-05-08 | Pfizer Products Inc. | Amide resorcinol compounds |
| PT2185561E (pt) * | 2007-07-27 | 2011-09-07 | Sanofi Aventis | Derivados de 1,2,3,4-tetra-hidropirrolo(1,2-a)pirazina-6- carboxamidas e de 2,3,4,5-tetra-hidropirrolo(1,2-a)-diazepina-7- carboxamidas, sua preparação e sua aplicação em terapia |
-
2013
- 2013-02-01 RU RU2014135759A patent/RU2650111C2/ru active
- 2013-02-01 EP EP13702225.7A patent/EP2809669B1/en active Active
- 2013-02-01 ES ES13702225T patent/ES2623167T3/es active Active
- 2013-02-01 HU HUE13702225A patent/HUE031729T2/en unknown
- 2013-02-01 UY UY0001034610A patent/UY34610A/es not_active Application Discontinuation
- 2013-02-01 CA CA2860933A patent/CA2860933C/en active Active
- 2013-02-01 AR ARP130100297A patent/AR089863A1/es unknown
- 2013-02-01 PL PL13702225T patent/PL2809669T3/pl unknown
- 2013-02-01 DK DK13702225.7T patent/DK2809669T3/da active
- 2013-02-01 US US14/375,273 patent/US9284333B2/en active Active
- 2013-02-01 CN CN201380007669.7A patent/CN104169281B/zh active Active
- 2013-02-01 KR KR1020147024134A patent/KR102017362B1/ko active IP Right Grant
- 2013-02-01 PT PT137022257T patent/PT2809669T/pt unknown
- 2013-02-01 AU AU2013214226A patent/AU2013214226B2/en active Active
- 2013-02-01 LT LTEP13702225.7T patent/LT2809669T/lt unknown
- 2013-02-01 BR BR112014018767-3A patent/BR112014018767B1/pt active IP Right Grant
- 2013-02-01 MX MX2014009356A patent/MX350793B/es active IP Right Grant
- 2013-02-01 WO PCT/EP2013/051996 patent/WO2013113860A1/en active Application Filing
- 2013-02-01 JP JP2014555214A patent/JP6126135B2/ja active Active
- 2013-02-01 SG SG11201403852UA patent/SG11201403852UA/en unknown
- 2013-02-01 SI SI201330622A patent/SI2809669T1/sl unknown
-
2016
- 2016-02-11 US US15/041,541 patent/US9884860B2/en active Active
-
2017
- 2017-04-19 HR HRP20170618TT patent/HRP20170618T1/hr unknown
- 2017-04-25 CY CY20171100459T patent/CY1119108T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| UY34610A (es) | Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos. | |
| CO7101248A2 (es) | Compuesos de tetrazolinona y su uso como pesticidas | |
| UY34817A (es) | Tienopirimidinas | |
| UY34605A (es) | Derivados de arilalquiloxipirimidina e insecticidas agrohortícolas que comprenden dichos derivados como principios activos, y método de uso de los mismos | |
| UY34820A (es) | Compuestos tipo pirrolo-pirrolidinona | |
| UY34585A (es) | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso | |
| UY34632A (es) | Compuestos de oxazolidin- 2- ona y usos de los mismos | |
| UY36311A (es) | Indazoles sustituidos con bencilo | |
| UY34648A (es) | Amidas como inhibidores de pim | |
| UY34763A (es) | Inhibidores de la agregación plaquetaria | |
| UY34306A (es) | Pirimidinas condensadas sustituidas y su uso | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| UY34797A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
| UY34201A (es) | Compuestos de azaindol y métodos para el tratamiento de vih. | |
| UY34550A (es) | Bencilpirazoles sustituidos | |
| UY34200A (es) | 3-(fluorovinil)pirazoles y su uso | |
| UY34778A (es) | ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?. | |
| UY34541A (es) | ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?. | |
| UY34539A (es) | Heteroarilos y usos de los mismos | |
| UY34448A (es) | NUEVOS DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3 | |
| AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
| UY34590A (es) | Fenilimidazopirazoles sustituidos y su uso | |
| UY34730A (es) | Formulaciones farmacéuticas que comprenden antagonistas de ccr3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211104 |